NAPA, Calif., Jan. 9 /PRNewswire/ -- Dey, L.P. today announced that it has settled a lawsuit brought against it and other companies by the State of Alabama in January 2005 pertaining to Medicaid reimbursements paid by the state to pharmacists and other healthcare providers. In exchange for a full release of claims, Dey has agreed to pay the state $4.75 million, $750,000 of which accounts for outside legal fees and expenses.
As part of the acquisition agreement between Mylan Inc. (Dey's parent company) and Merck KGaA (Dey's former parent company), Merck has agreed to indemnify Mylan in connection with this settlement and for all liability for all pending and future related Medicaid reimbursement lawsuits involving Dey.
As part of the settlement, the state acknowledges that the settlement does not constitute admission or evidence of fault, liability or unlawful conduct by Dey.
About Dey, L.P.
Dey, L.P., a subsidiary of Mylan Inc. (NYSE: MYL), is a specialty
pharmaceutical company focused on the development, manufacturing and
marketing of prescription drug products for the treatment of respiratory
diseases, respiratory-related allergies, and emergency care medicine. As
the U.S. leader in sales of nebulized respiratory medication, Dey, L.P.
puts patients first through its development of innovative and affordable
therapies. The Web sites for Dey, L.P. include http://www.dey.com,
http://www.accuneb.com, http://www.curosurfusa.com, http://www.cyanokit.com, http://www.du
'/>"/>
| SOURCE Dey, L.P. Copyright©2008 PR Newswire. All rights reserved |